首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IFNa5 |
| Uniprot No | P01569 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-189aa |
| 氨基酸序列 | MALPFVLLMALVVLNCKSICSLGCDLPQTHSLSNRRTLMIMAQMGRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSATWDETLLDKFYTELYQQLNDLEACMMQEVGVEDTPLMNVDSILTVRKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSANLQERLRRKE |
| 预测分子量 | 21,9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IFNa5重组蛋白的3篇代表性文献摘要：
1. **《Functional characterization of recombinant human interferon alpha 5 expressed in E. coli》**
- 作者：Zhang Y, et al.
- 摘要：研究在大肠杆菌中重组表达人IFNα5蛋白，优化纯化工艺并验证其抗病毒活性，发现其对乙型肝炎病毒复制的抑制效果优于IFNα2b。
2. **《Structural and receptor binding analysis of IFNα5 reveals subtype-specific features》**
- 作者：Li J, et al.
- 摘要：通过晶体结构解析发现IFNα5与干扰素受体的结合模式存在独特构象差异，解释了其与IFNα亚型在STAT信号通路激活效率上的不同。
3. **《IFNα5 recombinant protein enhances antitumor immunity in melanoma models》**
- 作者：Wang H, et al.
- 摘要：在小鼠黑色素瘤模型中，重组IFNα5通过激活CD8+ T细胞和抑制调节性T细胞，显著增强PD-1抑制剂疗效，提示其肿瘤免疫治疗潜力。
注：文献标题及作者为虚拟示例，实际研究中建议通过PubMed或Web of Science以"recombinant IFNα5"为关键词检索近期论文。
Interferon alpha-5 (IFNα5), a member of the type I interferon family, is a naturally occurring cytokine critical in mediating innate immune responses against viral infections and modulating adaptive immunity. Discovered in the 1980s, human IFNα5 is encoded by the IFNA5 gene located on chromosome 9. It shares structural homology with other IFNα subtypes, featuring a conserved core fold stabilized by disulfide bonds, but exhibits unique receptor-binding affinities and functional specificities due to subtle amino acid variations.
Recombinant IFNα5 is produced using biotechnological platforms, typically through expression in Escherichia coli or mammalian cell systems. The non-glycosylated bacterial product or glycosylated mammalian-derived protein is purified to >95% homogeneity, ensuring bioactivity comparable to native IFNα5. Its molecular weight ranges between 19-20 kDa depending on the expression system.
Functionally, IFNα5 activates the JAK-STAT signaling pathway by binding to the IFNAR1/IFNAR2 receptor complex, inducing interferon-stimulated genes (ISGs) that establish antiviral states in cells. Preclinical studies highlight its potent antiviral activity against hepatitis B/C viruses and herpesviruses, often exceeding other IFNα subtypes in specific contexts. It also demonstrates immunomodulatory effects, enhancing antigen presentation and T-cell responses, which underpins its exploration in cancer immunotherapy, particularly for hematologic malignancies.
Clinically, while IFNα2 remains the most therapeutically utilized subtype, IFNα5 has gained attention for its distinct pharmacokinetic profile and reduced toxicity in early-phase trials. Current research focuses on engineering PEGylated variants to extend half-life and evaluating synergistic effects with checkpoint inhibitors. Its role in autoimmune diseases and as a vaccine adjuvant is also under investigation, reflecting the expanding therapeutic potential of recombinant IFNα5.
×
